Skip to main content

Table 2 Characters for non-cancer participants in nine placebo-controlled and standard care-controlled statin trials

From: Intensified low-density lipoprotein-cholesterol target of statin therapy and cancer risk: a meta-analysis

Study Cancer outcome Relative LDL-c reduction endpoint LDL-c (mmol/L) New cancer cases Number in statin group Number in control group New cancer in satin group New cancer in control group
HPS CNS, Gastrointestinal, genitourinary, respiratory et al. 32.35 % 2.3 3493 10269 10267 1749 1744
AURORA Not specified 43 % 1.1 225 1389 1384 107 118
CARDS Not specified below 2.59 mmol/L 1.99 141 1428 1410 69 72
JUPITER Not specified 49 % 1.42 612 8901 8901 298 314
GDDS Not specified 42 % 1.86 83 619 636 39 44
ALLIANCE Not specified 34.30 % 2.5 144 1217 1225 67 77
PROSPER Gastrointestinal, genitourinary, respiratory et al. 34 % 2.5 444 2891 2913 245 199
LIPS Gastrointestinal, genitourinary, respiratory, CNS et al. below 2.59 mmol/L 2.48 32 844 833 14 18
4S Gastrointestinal 35 % 3.17 205 2221 2223 103 102
TOTAL     5379 29779 29792 2691 2688